Exclusive Report Series
Overpatented, Overpriced
Read I-MAK’s groundbreaking report on how excessive pharmaceutical patenting is extending monopolies and driving up drug prices. Featured in the New York Times and NBC News (last updated September 2022).
Why This? Why Now?
Using comprehensive research methodologies, I-MAK did a deep dive into patent and market data and compiled information that hasn't been available to the public - until now. We created a searchable database, a tool summarizing important market information on the top selling drugs, and a compelling report with key findings.
The Drug Patent Book
Searchable Database
This database is user-friendly tool with comprehensive patent data on the ten top selling drugs
Top Selling Drugs
Data Summary
A simple and easy resource that provides patent, pricing, spending, and market data for the ten top selling drugs in America.
Overpatented: 2022
Key Findings Report
Study highlights excessive patenting practices on blockbuster drugs, such as Revlimid, Humira and Enbrel, which impact cancer and arthritis.
Why I-MAK?
Partner with a Team Dedicated to
Impact Change For Generations
Through research, education, and policy, I-MAK is committed to finding solutions to address structural inequity in the medicines system.
Our team of lawyers, scientists, and global health experts empowers us to focus in three critical areas:
-
1
Research to
Influence Policy -
2
Education to
Activate Change -
3
Partnerships that
Drive Solutions
Featured In
Access Detailed Information on
America's Top-Selling Drugs
Read our investigations about everyday drugs that are overpatented and overpriced. Click each one to read more:
Learn more about how you can help build a more equitable system for all